Main Products/ Pipelines & Platforms
Ampholipad®: 1. AmBisome® generic injection for systemic fungal infection 2. Commercialized; TLC is eligible to earn royalties and milestones
Proprietary LNP platforms: BioSeizer® – Controlled release from days to months, extending therapeutic effects. NanoX® – Optimized targeted payload delivery, reducing off-target toxicity. Genosphere™ – Enabling disease-modifying RNA-based therapies for OA and beyond, opening new frontiers in precision medicine.
Main Pipelines: TLC590: Non-opioid extended-release (“ER”) injectable suspension TLC599: ER intraarticular injection TLC399: extended-release intra-ocular injection TLC178: Orphan drug for rare pediatric cancers TLC501 & TLC502 : Disease-modifying therapies for OA
Business Interests
Out-Licensing, Distribution, Strategic Alliance
Contact Info
Lindsey Yang
Sr. Associate, Office Admin & Facilities Management
+886-2-2655-7377 #125
lindsey@tlcbio.com